Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lowered by Leerink Swann from $568.00 to $502.00 in a research note released on Friday morning. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

Several other analysts have also commented on the stock. Robert W. Baird upgraded shares of Regeneron Pharmaceuticals from a neutral rating to an outperform rating in a research report on Friday. They noted that the move was a valuation call. Guggenheim set a $530.00 price target on shares of Regeneron Pharmaceuticals and gave the company a buy rating in a research report on Friday. Jefferies Group reiterated a hold rating and issued a $380.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday. BTIG Research downgraded shares of Regeneron Pharmaceuticals from a buy rating to a neutral rating and set a $480.00 price objective on the stock. in a research note on Thursday. Finally, BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $398.00 to $444.00 and gave the company a market perform rating in a research note on Thursday. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $463.19.

Shares of Regeneron Pharmaceuticals (REGN) opened at $336.38 on Friday. The company has a market cap of $36,140.33, a P/E ratio of 24.34, a PEG ratio of 1.27 and a beta of 1.47. Regeneron Pharmaceuticals has a 1 year low of $314.99 and a 1 year high of $543.55. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, beating the consensus estimate of $4.18 by $1.05. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.04 earnings per share. sell-side analysts predict that Regeneron Pharmaceuticals will post 14.13 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Harding Loevner LP raised its stake in shares of Regeneron Pharmaceuticals by 589.2% in the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after acquiring an additional 3,131,966 shares during the period. Polen Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.2% in the 4th quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock valued at $522,413,000 after acquiring an additional 15,931 shares during the period. American Century Companies Inc. raised its stake in shares of Regeneron Pharmaceuticals by 2.3% in the 3rd quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock valued at $410,257,000 after acquiring an additional 20,218 shares during the period. Orbimed Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 22.7% in the 3rd quarter. Orbimed Advisors LLC now owns 572,770 shares of the biopharmaceutical company’s stock valued at $256,097,000 after acquiring an additional 106,000 shares during the period. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Regeneron Pharmaceuticals by 93.5% in the 4th quarter. UBS Asset Management Americas Inc. now owns 553,501 shares of the biopharmaceutical company’s stock valued at $208,094,000 after acquiring an additional 267,442 shares during the period. 65.89% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals (REGN) Price Target Lowered to $502.00 at Leerink Swann” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/02/12/regeneron-pharmaceuticals-regn-price-target-lowered-to-502-00-at-leerink-swann.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.